Most patients had T1 or T2 tumours (HR-low/HER2-negative BC: 71.4%; TNBC: 64.7%), positive nodal status (HR-low/HER2-negative BC: 68.6%; TNBC: 63.3%), and invasive ductal carcinoma (HR-low/HER2-negative BC: 94.3%; TNBC: 89.4%). The gene discussed is ERBB2; the disease is breast cancer.